Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EBIT (2019 - 2025)

Historic EBIT for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$1.0 million.

  • Cyclerion Therapeutics' EBIT rose 1081.56% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year increase of 3868.35%. This contributed to the annual value of -$3.6 million for FY2024, which is 7198.67% up from last year.
  • As of Q3 2025, Cyclerion Therapeutics' EBIT stood at -$1.0 million, which was up 1081.56% from -$1.7 million recorded in Q2 2025.
  • Cyclerion Therapeutics' EBIT's 5-year high stood at $502000.0 during Q4 2024, with a 5-year trough of -$16.2 million in Q2 2021.
  • For the 5-year period, Cyclerion Therapeutics' EBIT averaged around -$6.2 million, with its median value being -$4.5 million (2022).
  • In the last 5 years, Cyclerion Therapeutics' EBIT plummeted by 3313.41% in 2023 and then surged by 12796.66% in 2024.
  • Over the past 5 years, Cyclerion Therapeutics' EBIT (Quarter) stood at -$14.3 million in 2021, then skyrocketed by 68.93% to -$4.5 million in 2022, then surged by 59.71% to -$1.8 million in 2023, then surged by 127.97% to $502000.0 in 2024, then plummeted by 300.4% to -$1.0 million in 2025.
  • Its EBIT stands at -$1.0 million for Q3 2025, versus -$1.7 million for Q2 2025 and -$1.5 million for Q1 2025.